TY - JOUR
T1 - In vitro and in vivo investigations on the antitumour activity of Chelidonium majus
AU - Rica Capistrano, I.
AU - Wouters, An
AU - Lardon, Filip
AU - Gravekamp, Claudia
AU - Apers, Sandra
AU - Pieters, Luc
N1 - Funding Information:
The Agency for Innovation by Science and Technology in Flanders (IWT) is acknowledged for granting a PhD fellowship to R.C. Operational expenses were in part defrayed by a research project of L.P. with the Anticancer Fund ( www.anticancerfund.org , a non-profit organization), which is acknowledged for scientific and financial support. We would also like to thank Dr. Lieve Coenegrachts and Prof. Dr. Frederic Amant from the Laboratory of Gynaecologic Oncology at KU Leuven for their assistance with the xCELLIgence experiments. The authors declare to have no conflict of interest.
Publisher Copyright:
© 2015 Elsevier GmbH. All rights reserved.
PY - 2015/12/15
Y1 - 2015/12/15
N2 - Background Chelidonium majus L. (Papaveraceae) (greater celandine) is a medicinal herb that is widely spread in Europe. Antitumoural activity has been reported for C. majus extracts. Hypothesis/Purpose To investigate the antitumour activity of a C. majus extract in vitro and in vivo. Study Design Cytotoxic effects of C. majus extracts were evaluated on human cancer cell lines, i.e. PANC-1 (pancreas cancer), HT-29 (colon cancer), MDA-MB-231 (breast cancer), PC-EM005 and PC-EM002 (primary endometrium cancer cells), and PANC02 (murine pancreatic adenocarcinoma cells). A preliminary in vivo study was performed to evaluate the effect of a defatted C. majus extract and UkrainTM in a highly metastatic murine pancreatic model. Methods Chelidonium majus L. herb containing 1.26% (dry weight) of total alkaloids expressed as chelidonine was used to prepare an 80% ethanolic extract (CM2). This crude extract was then defatted with n-hexane, resulting in a defatted C. majus extract (CM2B). Cytotoxic effects of the two extracts (CM2 and CM2B) were evaluated on human and murine cell lines in vitro. CM2B and UkrainTM were evaluated in a highly metastatic murine pancreatic model. Results Four main benzylisoquinoline alkaloids were identified in CM2B, i.e. chelidonine, sanguinarine, chelerythrine and protopine, using HPLC-UV. CM2 showed a high cytotoxic activity against PANC-1 (IC50, 20.7 μg/ml) and HT-29 (IC50, 20.6 μg/ml), and a moderate cytotoxic activity against MDA-MB-231 (IC50, 73.9 μg/ml). CM2 as well as CM2B showed a moderate to high cytotoxic activity against the PANC02 cell line (IC50, 34.4 and 36.0 μg/ml). Low to almost no cytotoxic effect was observed on primary endometrium cancer cells PC-EM005, PC-EM002 and on normal fibroblast cells 3T3, when treated with CM2B. Significantly less metastases were counted in mice treated with 1.2 mg/kg CM2B, but not with 3.6 mg/kg UkrainTM, compared to the control group. The extract, however, did not affect the weight of the primary tumours.
AB - Background Chelidonium majus L. (Papaveraceae) (greater celandine) is a medicinal herb that is widely spread in Europe. Antitumoural activity has been reported for C. majus extracts. Hypothesis/Purpose To investigate the antitumour activity of a C. majus extract in vitro and in vivo. Study Design Cytotoxic effects of C. majus extracts were evaluated on human cancer cell lines, i.e. PANC-1 (pancreas cancer), HT-29 (colon cancer), MDA-MB-231 (breast cancer), PC-EM005 and PC-EM002 (primary endometrium cancer cells), and PANC02 (murine pancreatic adenocarcinoma cells). A preliminary in vivo study was performed to evaluate the effect of a defatted C. majus extract and UkrainTM in a highly metastatic murine pancreatic model. Methods Chelidonium majus L. herb containing 1.26% (dry weight) of total alkaloids expressed as chelidonine was used to prepare an 80% ethanolic extract (CM2). This crude extract was then defatted with n-hexane, resulting in a defatted C. majus extract (CM2B). Cytotoxic effects of the two extracts (CM2 and CM2B) were evaluated on human and murine cell lines in vitro. CM2B and UkrainTM were evaluated in a highly metastatic murine pancreatic model. Results Four main benzylisoquinoline alkaloids were identified in CM2B, i.e. chelidonine, sanguinarine, chelerythrine and protopine, using HPLC-UV. CM2 showed a high cytotoxic activity against PANC-1 (IC50, 20.7 μg/ml) and HT-29 (IC50, 20.6 μg/ml), and a moderate cytotoxic activity against MDA-MB-231 (IC50, 73.9 μg/ml). CM2 as well as CM2B showed a moderate to high cytotoxic activity against the PANC02 cell line (IC50, 34.4 and 36.0 μg/ml). Low to almost no cytotoxic effect was observed on primary endometrium cancer cells PC-EM005, PC-EM002 and on normal fibroblast cells 3T3, when treated with CM2B. Significantly less metastases were counted in mice treated with 1.2 mg/kg CM2B, but not with 3.6 mg/kg UkrainTM, compared to the control group. The extract, however, did not affect the weight of the primary tumours.
KW - Chelidonium majus L.
KW - Greater celandine
KW - In vitro cytotoxicity
KW - In vivo antitumor activity
KW - Papaveraceae
UR - http://www.scopus.com/inward/record.url?scp=84949526560&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84949526560&partnerID=8YFLogxK
U2 - 10.1016/j.phymed.2015.10.013
DO - 10.1016/j.phymed.2015.10.013
M3 - Article
C2 - 26626193
AN - SCOPUS:84949526560
SN - 0944-7113
VL - 22
SP - 1279
EP - 1287
JO - Phytomedicine
JF - Phytomedicine
IS - 14
ER -
